From the Wires
Sets up US subsidiary
Nov. 26, 2012 02:05 AM
YORK, UK -- (Marketwire) -- 11/26/12 --
Tissue Regenix sets up United States subsidiary
to target growing regenerative medicine market
Tissue Regenix appoints Greg Bila President, Tissue Regenix USA
YORK, 26 November 2012. Tissue Regenix Group plc ('Tissue Regenix') has
set up a subsidiary company in the United States, as part of its
commercialisation strategy for its dCELL® technology platform.
Tissue Regenix is also pleased to announce the recruitment of Greg Bila
from Kinetic Concepts Inc. ('KCI') as President of Tissue Regenix USA.
Greg's recent career at KCI has spanned a number of sales & marketing
roles and brings over 20 years' experience in pharmaceutical and
medical device fields.
Tissue Regenix will use its patented dCELL® technology to target a
number of areas. Work will focus initially on applying the dCELL® to
the treat a number of chronic diseases but, over time, could be
developed for other applications including vascular repair, heart valve
replacement and knee repair. Tissue Regenix's dCELL® technology have
delivered encouraging interim data.
Antony Odell, Managing Director of Tissue Regenix commented: "This is a
significant step in the development of Tissue Regenix. It is an
excellent signal of the strength of TR's proposition that we can
attract people of Greg's calibre and experience, we look forward to
advancing our plans in the US with him at the helm. The United States
presents an opportunity to establish our platform dCELL® technology in
a market potentially worth hundreds of millions of dollars."
Greg Bila, President of Tissue Regenix Wound Care Inc. said: "I am
excited to be able to join Tissue Regenix at the beginning of its
expansion into the United States. TR's dCELL® technology will be a
welcome offering for the treatment of number of diseases and the
potential indications are attractive."
The potential advantages of the Company's dCELL technology over other
types of decellularised tissue scaffolds was underpinned at Tissue
Regenix technology day in October by Dr Alan Dardik, Associate
Professor of Surgery at Yale University, who has conducted pre-clinical
studies of Tissue Regenix dCELL® vascular patch and published the
results in the scientific journal PLoS ONE.
Speaking about those studies Dr Dardik commented: "I have to say my
impression is it's the closest thing on the market to a tissue
engineered patch. It's the next technology. Other companies are trying
to attract stem-cells but they've already got the stem cells that are
coming into their patch."
For Further Information
Tissue Regenix Group plc: 01904 435 176
Alistair Kellie 07801 234598
Andrew Adie 07970 256512
Martin Greig 07584 221513
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of
regenerative medicine. The company's patented decellularisation
('dCELL®) technology removes DNA and other cellular material from
animal and human tissue leaving an acellular tissue scaffold which is
not rejected by the patient's body which can then be used to repair
diseased or worn out body parts. The potential applications of this
process are diverse and address many critical clinical needs such as
vascular disease, heart valve replacement and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.
This information is provided by RNS
The company news service from the London Stock Exchange